Stay updated with breaking news from Thyroid Imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NorthStar’s Mo-99 program continues at the forefront of U.S. radioisotope production as the only commercialized producer of key medical radioisotopes molybdenum-99 (Mo-99)/technetium-99m (Tc-99m
Introduction Thyroid nodules are very common. However, the majority of thyroid nodules are benign. Ultrasound is the first-line imaging investigation of choice for thyroid nodules. Certain sonographic features are associated with an increased risk of malignancy. Recent studies suggested that the location of the nodule may be associated with the malignancy risk. Hence, this study aims to investigate this association. Methods After obtaining approval from the ethics committee, we conducted a retrospective study that involved all patients who attended our hospital, and who underwent fine-needle a...
High precision for T stage, extracapsular extension, BRAF mutation
With next-generation refinement, Thyroid Imaging, Reporting, and Data System (TI-RADS) grading can assist in diagnosing questionable thyroid nodules.
Posted on 407 NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and therapeutic treatments, today announced that the U.S. Food and Drug Administration (FDA) has approved its application for producing Mo-99 from concentrated Mo-98 (cMo-98) and related software updates for the RadioGenix® System (technetium Tc 99m generator). Processing of cMo-98 targets increases production capacity of the important medical radioisotope, molybdenum-99 (Mo-99)...